Ultragenyx Pharmaceutical Inc. 8-K

What Happened
On February 3, 2026 Ultragenyx Pharmaceutical Inc. announced new long-term clinical data for UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA). The company reported substantial and durable reductions in cerebrospinal fluid heparan sulfate (CSF‑HS) and meaningful functional benefits versus natural history, and said UX111 was generally well tolerated. The data will be presented orally at WORLDSymposium™ 2026 on February 6, 2026. These longer-term results were included in a resubmitted Biologics License Application (BLA) to the FDA; Ultragenyx expects a PDUFA date in the third quarter of 2026.

Key Details

• Cognitive improvement vs natural history in younger/earlier-stage treated children (n=17): +23.2 points mean Bayley‑III cognitive raw score (p<0.0001) during 24–60 months of age.
• Other Bayley‑III subtest improvements (younger/earlier-stage): receptive communication +8.1 (p=0.0076); expressive communication +11.1 (p=0.0008); fine motor +9.0 (p=0.0026); gross motor +3.9 (p=0.070).
• Biomarker: median CSF‑HS exposure reduction 63.98% (p<0.001) in overall efficacy set (N=27) as of Sept 2025; ≥50% reduction achieved in ~81.5% overall (88.2% in younger patients).
• Safety and follow‑up: UX111 generally well tolerated across doses (N=33), median follow‑up 4.8 years (0.6–8.5). Most common events were liver enzyme elevations; no infusion-related anaphylaxis, thrombotic microangiopathy, myocarditis, dorsal root ganglion toxicity, or malignancy reported.
• Later‑stage patients (n=10): functional retention at last assessment — all retained communication; 9/10 retained independent ambulation; 9/10 maintained oral feeding/self‑feed.
• Regulatory: BLA resubmitted to FDA; company anticipates up to a six‑month review window from resubmission with an expected PDUFA date in Q3 2026.

Why It Matters
These results provide both biomarker and clinical-function evidence that the treatment may alter the typical course of MPS IIIA—supporting Ultragenyx’s resubmitted BLA and the company’s regulatory timeline. For investors, the key near-term milestone is the FDA review/PDUFA expected in Q3 2026; a favorable decision could enable commercialization for a severe pediatric disease with high unmet need. Safety findings reported here (no major immune or neurologic toxicities observed) and the durable biomarker response may reduce regulatory risk, but final approval and commercial outcomes remain subject to FDA review.